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1. Introduction 
Parkinson’s disease (PD) is the most common neurodegenerative movement disorder that is 
estimated to affect approximately 1% of the population older than 65 years of age (deRijk et 
al., 2006; Saunders, 2000). PD was first described in 1818 by the British physician J. 
Parkinson. Before that date, no one had ever described the symptoms of this disease; so 
many researchers theorize that this pathology is the product of the English Industrial 
Revolution (Parris, 2000; Perlmutter, 2000). Some authors speculate that new neurotoxic 
contaminants produced by the industries can have been the cause of this chronic and 
progressive disease. PD is characterized by the progressive depletion of pigmented 
dopamine-containing neurons in the region known as the substantia nigra pars compacta 
and by the presence of intraneuronal aggregates called Lewy bodies (LBs), which are 
enriched in filamentous -synuclein and other proteins that are often ubiquinated (Lee & 
Trojanowsky, 2006). Approximately 80% of dopaminergic neurons in the substantia nigra 
are already irreversibly destroyed when the symptoms of PD becomes significantly visible. 
Depletion of dopamine causes dysregulation of the motor circuits that project throughout 
the basal ganglia (BG), resulting in the cardinal clinical manifestations of PD: bradykinesia 
(extreme slowness), tremor, rigidity, and postural instability. Consequently, patients 
experience increasing difficulty in daily living functions along the course of the disease. 
Additional neuronal fields and neurotransmitter systems are also involved in PD, including 
the locus coeruleus, the dorsal motor nucleus, the autonomic nervous system and the 
cerebral cortex. Consequently, noradrenergic, serotoninergic, and cholinergic neurons are 
also lost. These widespread neuronal changes led to complex and variable progressive non-
motor symptoms such as cognitive decline, sleep abnormalities, and depression which 
dominate the later stages of PD (Braak, 2003). In any case, PD is primarily a sporadic 
disorder and its etiopathogenesis is still not fully understood, but the recent discovery of 
genes associated with rare monogenic forms of the disease, together with earlier studies and 
new experimental animal models, has provided important and novel insight into the 
molecular pathways involved in disease pathogenesis (Wood-Kaczamar, 2006). Increasing 
evidence indicates that deficits in mitochondrial function, oxidative and nitrosative stress, 
accumulation of aberrant or misfolded proteins, and ubiquitin-proteasome system 
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dysfunction can represent the principal molecular pathways or events that commonly 
underlie the pathogenesis of sporadic and familial forms of PD (Schapira, 2008). However it 
is possible that multiple factors contribute to the cascade of events leading to cells death in 
patients with PD and that different factors might be more important in different individuals 
(Olanow, 2009) (Fig. 1).  
 
 
Fig. 1. Schematic illustration of factors that might be involved in the pathogenesis of cells 
death in PD. (Adapted from Olanow, 2007).  
Several pharmacological agents are currently available for the management of PD (Table 1). 
These drugs can provide symptomatic relief but no agents capable to halt the progression of 
the neurodegenerative process or reverse the neuronal degeneration have been developed 
yet. Moreover, the neuroprotective effects suggested for many of the approved drugs have 
not been convincingly demonstrated in PD patients. Furthermore, although PD also 
involves degeneration of non-dopaminergic neurons, the treatment of the resulting 
predominantly non-motor features remains a challenge. The leading therapeutic strategy 
pursued in PD management is the so called dopamine replacement therapy (DRT), which 
employs drugs acting on dopamine (DA) circuits to restore the deficient dopaminergic tone 
existing in this pathology. Pharmacological agents have also been developed which can 
indirectly boost DA transmission, based on the functional interactions existing between DA 
and other neurotransmitters in the BG. L-Dopa is the key compound in the treatment of PD, 
acting as a precursor of DA. It has a long clinical record as the most effective 
antiparkinsonian drug, and it is still considered the “gold standard” in pharmacological 
treatment of PD (Mercuri & Bernardi, 2005). However, besides offering only symptomatic 
relief for patients, motor and non-motor untoward effects are often observed in the course of 
L-dopa therapy, which can be severe and limit its therapeutic potential (Encarnation & 
Hauser, 2008; Fox & Lang, 2008). Furthermore, exposure of patients to L-dopa, results in 
fluctuations of motor responses in approximately 30–50% of patients exposed to therapy for 
as little as 5 or more years. The most common fluctuation experienced is the so-called “on-  
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Table 1. Currently available pharmacological therapies for PD treatment. 
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off” phenomenon that results in an unpredictable transient loss of therapeutic effect. Apart 
from L-dopa, drugs that are currently prescribed for the management of PD include DA 
receptor agonists, selective monoaminooxidase type B inhibitors (MAO-B), catecol-O-
methyltransferase (COMT) inhibitors, amantadine (an antiviral agent that also bears action 
as an antiglutamatergic agent), and anticholinergics. DA receptor agonists counteract PD-
associated motor impairment chiefly stimulating the D2-like receptors, though some of them 
can also bind non–dopaminergic receptors. They may be used alone to delay the need for L-
dopa or as multiple-medication therapy (MMT) with L-dopa to increase its effectiveness 
(Cavalli et al. 2008). Neuroprotective properties have been suggested for some 
dopaminergic agonists (e.g. bromocriptine and pramipexole), although the clinical evidence 
collected so far does not convincingly support this hypothesis (Schapira, 2003). Certain other 
available drugs, like MAO-B (Fernandez & Chen, 2007) and COMT inhibitors (Canesi et al., 
2008; Schrag, 2005), are used mainly as MMT with L-dopa, since they alter the in vivo 
metabolism of DA by increasing its plasma half-life. Functional interactions between 
glutamate and DA receptors exist in BG, and evidence suggests that the loss of DA in PD 
may lead to glutamatergic hyperactivity, which participates in the manifestation of motor 
impairment accompanying the disease (Chase & Oh, 2003). On this basis, glutamatergic 
antagonists have been extensively investigated as potential antiparkinsonian drugs (Johnson 
et al. 2009). Among these, amantadine is the best characterized antiglutamatergic agent used 
in PD management. In addition to the blockade of ionotropic N-methyl-D-aspartate 
(NMDA) receptors, amantadine posses other mechanisms of action which contribute to its 
effects: anticholinergic activity, stimulation of DA release, modulation of the affinity of post-
synaptic DAergic receptors for DA (Metman et al., 1998, Peeters et al., 2003). Anticholinergic 
compounds were the first, and for a long time the only, pharmacological agents available to 
treat motor deficits accompanying PD (Brocks, 1999). They were intend to correct the 
imbalance between DA and acetylcholine levels that take place in the BG, where a reduction 
of cholinergic tone may amplify DA-mediated signal (Cragg, 2006). Although these drugs 
produce some beneficial effects on PD symptoms, they are associated with adverse cognitive 
effects (Cancelli et al., 2009). All the anticholinergics used against PD bind to the central 
muscarinic receptors, having no affinity for the nicotinic ones, although they also block 
peripheral muscarinic receptors, and this triggers many of their adverse effects, which 
include nausea, constipation and urinary retention (Lees, 2005). Nevertheless, currently 
available pharmacological therapies are unable to arrest or to reverse the progression of this 
relentlessly progressive and severely debilitating condition. PD is currently an incurable 
disease, and the number of subjects afflicted with this disease is constantly increasing due 
to the increasing global geriatric population. Therefore, the need for newer and more 
effective agents is receiving a great deal of attention and, consequently, being subjected to 
extensive research. The vast amount of information gained regarding the pathogenesis of 
PD has fuelled numerous developments and vast range of investigated agents have 
demonstrated immense potential for preventing and eventually providing cure for this 
condition. Clinical and biochemical evidences suggest that PD involves multifactorial, 
oxidative neurodegeneration and that L-dopa therapy aggravates the oxidative burden. 
Strong evidence now exists to support an aberrant role for mitochondrial functions, as 
well as increased oxidative stress, in the pathogenesis of PD. If mitochondrial defects and 
oxidative damage play a role in the pathogenesis of PD, then one would suspect that 
www.intechopen.com
 
Acetyl-L-Carnitine in Parkinson’s Disease 
 
371 
agents that may improve mitochondrial function or exert antioxidative effects could be 
neuroprotective. There are several agents that are currently under investigation for their 
potential neuroprotective effects based on their capacity to modify mitochondrial 
dysfunction. These include creatine, coenzyme Q10, nicotinamide, lipoic acid and acetyl-
L-carnitine, etc. (Table 2). These agents are therefore promising candidates for 
neuroprotective drugs against PD (Beal, 2003). Acetyl-L-carnitine, (3R)-3-(acetyloxy)-4-
(trimethylammonio)butanoate (table 2), is an ester of the trimethylated amino acid, L-
carnitine, and is synthesized in the brain, liver and kidney by the enzyme acetyl-L-
carnitine transferase. Acetyl-L-carnitine facilitates the transport of fatty acids and other 
moieties across the membranes of mitochondria, thereby participating in the production 
of energy and mitochondrial function within the brain. Acetyl-L-carnitine has been 
proposed to have beneficial effects in preventing the loss of brain functions which 
typically occur during aging and neurodegenerative disorders. The main mechanism of 
action of acetyl-L-carnitine is the improvement of mitochondrial respiration which allows 
the neuron to produce ATP necessary to maintain the normal membrane potential. 
However, acetyl-L-carnitine has been shown to be neuroprotective through a variety of 
other effects such as the increase in protein kinase C (PKC) activity (McDaniel, et al. 2003). 
Moreover acetyl-L-carnitine has also been reported to attenuate the occurrence of 
parkinsonian symptoms associated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP) in vivo, and protects in vitro against the toxicity of neurotoxic 1-methyl-4-
phenylpyridinium (MPP+), a metabolite of MPTP (Hongyu et. al., 2010). Therefore, acetyl-
L-carnitine with its well known antioxidant energizing protective activities and with its 
trophic effects, might be an effective and safe prevention strategy for PD. 
 
 
 
Agent Structure 
Coenzyme Q10 
O
O
H3CO
H3CO
( )8
 
Carnitine 
OH
N
+
COO
-
Acetyl-L-carnitine 
N
+
O
COO
-
O
Lipoic acid 
S S
COOH
www.intechopen.com
 
Mechanisms in Parkinson’s Disease – Models and Treatments 
 
372 
Agent Structure 
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Table 2. Neuroprotective agents effective in PD models. 
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2. Nutritional and biochemical aspects of acetyl-L-carnitine 
Carnitine has been discovered in the bovine muscle in 1905, but its structure was defined only 
in 1927. In 1958 the role of carnitine has been discovered by I. Frizz, who demonstrated that 
this substance is important in stimulating the oxidation of long chain fatty acids into the 
mitochondria. L-Carnitine (‒)-3-hydroxy-4-(trimethylammonio)butanoate is a highly polar, 
water-soluble quaternary amine that exists as a zwitterion under physiological conditions. 
It was initially called vitamin T, because it is necessary for the growth of the Tenebrio 
Molitor warm. Although it is structurally similar to an amino acid it is not involved in the 
formation of proteins, and it is more similar to acetylcholine. Carnitine is synthesized in 
vivo from the amino acids lysine and methionine, especially in liver, kidney, and muscle, 
and it is stored mainly in skeletal and cardiac muscles (Marquis & Fritz, 1965). Exogenous 
carnitine, taken predominantly with the meat of the diet, is about 75% of the body 
carnitines, while the daily requirement is about 200—300 mg. In vivo synthesis of 
carnitine, supplemented by carnitine from diet, provides sufficient carnitine to maintain 
metabolic functions. However, in cases of excessive loss of carnitine (low carnitine intake 
with the diet, altered carnitine metabolism or disease states such as in neurodegenerative 
diseases and geriatric depression), supplementation with acetyl-L-carnitine may be 
beneficial. Tissue levels of L-carnitine in animals and humans decrease with age, due to 
reduced integrity of the mitochondrial membranes. Acetyl-L-carnitine, an ester of the L-
carnitine, is synthesized in human brain, liver, and kidney by the enzyme acetyl-L-
carnitine transferase. Carnitine, acetyl-L-carnitine and acyl-L-carnitine are responsible for 
many biological actions. Several authors have suggested that acetyl-L-carnitine has 
beneficial effects on brain functions during aging and in conditions of neurodegenerative 
diseases such as Parkinson’s and Alzheimer’s diseases. It has been demonstrated that 
acetyl-L-carnitine plays a role in increasing the potency of cholinergic and anti-cholinergic 
actions, by reacting with the electrophilic or cationic site of the cholinergic receptor 
(Sinicropi et al., 2010). Carnitine as acyl-L-carnitine is important in the mitochondrial 
process of -oxidation of fatty acids (Bremer, 1962; Bremer et al., 1983) and the acetyl 
moiety can be utilized to maintain acetyl-CoA levels. Acetyl-L-carnitine promotes 
acetylcholine production and release, and stimulates membrane phospholipid synthesis 
(Pettegrew et al., 2000). In addition, the acetyl moiety of acetyl-L-carnitine can acetylate –
NH2 and/or –OH functional groups of lysine, serine, threonine, tyrosine and N-terminal 
amino acids in proteins modifying their structure, function and activity. Moreover acetyl-
L-carnitine modulates glucose metabolism and stimulates glycogen synthesis, restores 
ammonia induced depletion of brain energy stores in sparse-fur mice with elevated 
ammonia and glutamine levels (Rao et al., 1997) and, with carnitine, maintains 
progressive spermatozoa motility (Jeulin et al., 1988). This molecule acts also on the 
mitochondrial redox reactions that allow neurons to produce ATP, required to maintain 
normal membrane potential (McDaniel et al., 2003). L-carnitine and acetyl-L-carnitine are 
administrated orally, intravenously and/or intramuscularly. These compounds are 
absorbed in the jejunum by simple diffusion. Transport into tissues and cells is via an 
active transport mechanism and acetyl-L-carnitine and carnitine plasma concentrations 
reach equilibrium via carnitine acetyl-transferase activity. Both intravenous and oral 
administrations result in a corresponding increase of cerebrospinal fluid (CSF) 
concentrations of acetyl-L-carnitine, indicating that it readily crosses the blood-brain 
barrier (Kido et al., 2001; Thal et al., 1996). 
www.intechopen.com
 
Mechanisms in Parkinson’s Disease – Models and Treatments 
 
374 
3. MPTP and neuroprotective effect of acetyl-L-carnitine in pathogenesis of 
Parkinson’s disease 
In the mitochondria of all cells redox reactions produce free radicals. High levels of reactive 
oxygen species (ROS) and reactive nitrogen species (RNS), especially in Parkinson’s disease, 
can result in damage to phospholipids and polyunsaturated fatty acids, which are both 
abundant in the brain and therefore susceptible to oxidative damage. Therefore, there are 
many evidences for increased oxidative damage also to DNA and proteins (Dexter et al., 
1994). Many evidences have accumulated implicating mitochondrial defects and oxidative 
stress damage in the pathogenesis of Parkinson’s disease. In this contest, fundamental role is 
attributed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a neurotoxin that is able 
to produce an experimental model of Parkinson's disease (PD) in humans and laboratory 
animals (such as primates and mice). It replicates most of the clinical features of PD as well 
as the main biochemical and pathologic hallmarks of the disease. The apparent neurotoxic 
specificity of MPTP is mediated through its conversion into 1-methyl-4-phenylpyridine 
(MPP+) (Fig. 2) by the action of the mitochondrial enzyme MAO B (Javitch & Snyder, 1984; 
Javitch et al., 1985).  
 
 
Fig. 2. Conversion of MPTP in MPP+ 
The neurotoxicity of MPTP was discovered in 1976 when B. Kidstone, a 23 years old student 
of chemistry in Maryland, synthesized MPTP and injected it himself. He was contaminated 
by the MPTP and three days later he showed all the symptoms of Parkinson’s disease. 
Studies on MPTP toxicity showed that it is mediated by inhibition of respiratory chain 
complex I activity (Bloem et al., 1990). There are at least three ways that MPP+ can follow 
once inside dopaminergic neurons (Przedborski & Vila, 2003). It can: a) take the vesicular 
pathway, bind to dopamine transporters to be translocated into synaptosomal vesicles (Liu 
et al., 1992); b) interact with various cytosolic enzymes by remaining into the cytosol 
(Klaidman et al., 1993); c) be concentrated in the mitochondria (Ramsay & Singer, 1986). 
MPP+ can passively enter the mitochondria through the transmembrane potential of the 
mitochondrial membranes and it can accumulate into the mitochondrial matrix. First of all, 
MPP+, after being entered the mitochondrial matrix, inhibits the Krebs cycle enzyme -
ketoglutarate dehydrogenase (Mizuno et al., 1987), but the main cause of mitochondrial 
dysfunction involves the respiratory chain complex I (Ramsay et al., 1991). The MPP+ 
toxicity is associated with oxidative damage. In fact MPP+ induces superoxide production 
and increases lipid peroxidation. Important studies of Dexter and colleagues, showing 
increases in both malondialdehyde and in cholesterol hydroperoxides, led to a direct 
evidence of oxidative damage in Parkinson’s disease (Dexter et al., 1994). Even the 
concentration of 8-hydroxy-2’-deoxyguanosine has been found three to four times higher in 
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the caudate and substantia nigra of Parkinson’s disease subjects (Sancher-Ramos et al., 
1994). Shergill and co-authors have found a significant increase of nitrosyl complexes in 
Parkinson’s disease substantia nigra (Shergill, 1996). However, recent studies suggest that 
MPP+ toxicity, at least in the initial stages, is primarily due to a decrease in mitochondrial 
ATP synthesis rather than the formation of free radicals (Fonck & Baudry, 2003). 
Subsequently, the protective effect of acetyl-L-carnitine in Parkinson’s disease, induced by 
MPTP, has been studied in a group of primates by the research group of Bodis-Wolner 
(Bodis-Wolner et al., 1991). For their studies Bodis-Wolner and colleagues used three groups 
of primates, the first of which was treated just with MPTP. To the second group was 
administered acetyl-L-carnitine before the MPTP, while the third group had a control role. 
Their results have shown that primates treated only with MPTP developed the classic 
symptoms of parkinsonism. In the second group, only in a primate a weak form of 
Parkinson’s disease has evolved to signify the protective effect of acetyl-L-carnitine on the 
disease development. It is conceivable that the effect of MPP+ results in altering the 
mitochondrial respiration processes linked to NAD (Nicklas et al., 1985, 1987; Heikkila et al, 
1985; Ramsey et al., 1986; Mizuno et al., 1988).  
4. Toxic and antioxidant compounds in Parkinson’s disease 
Oxidants, as hydrogen peroxide and superoxide radicals, are produced as by-products of 
oxidative phosphorylation into mitochondria, making these organelles the main site of ROS 
generation within the cells. In fact, mitochondria are a major source of ROS, with up to 2-3 % 
of all oxygen consumed by mitochondria being converted to hydrogen peroxide (Boveris et 
al., 1972). This is the normal condition and basal levels of ROS can be limited by the 
presence of efficient antioxidant defence systems, including the enzymatic antioxidants 
(superoxide dismutase, catalase, peroxidases, and heme oxygenase) and the non-enzymatic 
redox-regulating antioxidants (glutathione and vitamin C). However, in pathological 
neurodegenerative conditions, like in Parkinson’s disease, where mitochondrial respiratory 
defects occur, the amount of ROS produced by the electron transport chain dramatically 
increases, abolishing the antioxidant protection systems (Parker et al., 1989). In studies on 
brain tissue in patients with PD, the activity of complex I is reduced in the substantia nigra, 
without any decrease in other brain regions. As shown by Haas et al. (Hass et al., 1995), the 
activity of complex I is reduced also in PD platelets of un-medicated patients. A decrease of 
coenzyme Q10 levels in platelets mitochondria, which is correlated with reduced complex I 
of respiratory chain, is reported in Shults et al. (Shults et al., 1997). In parkinsonian subjects 
platelets mitochondria were found to have lower levels of coenzyme Q10 than mitochondria 
from age/sex-matched controls. As shown in certain clinical studies, coenzyme Q10 appears 
to slow the progressive deterioration of function in PD (Shults et al., 2002). Coenzyme Q10 is 
necessary for the normal activity of the respiratory chain and transfers electrons from 
complexes I and II to III. It can be worthwhile to use coenzyme Q10 to restore the functions 
of the respiratory chain and scavenge ROS. Nevertheless, coenzyme Q10 protects primary 
dopaminergic neurons in vitro against cell death induced by MPTP (Gille et al., 2004), and 
seems that at least partially restores the function of complex I in the tissues of patients with 
PD (Shults et al., 1998; Storch et al., 2007). Moreover, it has antioxidant properties; it has 
been also shown to prevent peroxidation of membrane lipids and protect mitochondrial 
DNA from free oxygen radicals. Important results on the defects of complex I activity in the 
pathogenesis of PD are derived from studies with the toxin rotenone. Rotenone (Table 3) is a 
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natural compound extracted from the roots of certain plants and has been used as an 
insecticide for vegetables. Rotenone rapidly crosses the blood-brain barrier due to its 
lipophilic structure, and rapidly crosses the biological membranes of mitochondria into the 
cells, in which the toxin reduces the activity of oxidative phosphorylation, by binding to 
PSST subunit of respiratory chain complex I (Schuler & Casida, 2001). It is known that 
rotenone is a highly specific inhibitor of complex I of the electrons transport chain. The 
possibility that rotenone and other pesticides are involved in the pathogenesis of PD stems 
from epidemiological studies (Gorell et al., 1998; Seidler et al., 1996). In fact, an atypical 
Parkinson's syndrome has developed in populations of the French West Indies, taking fruit 
and herbal tea containing insecticides (Caparros-Lefebvre & Elbaz, 1999). Pesticides and 
herbicides become highly suspect as potential PD triggers. A connection was long suspected 
between PD and rural living, including the drinking of contaminated well water or exposure 
to pesticides and herbicides (Hancock et al., 2008; Stephenson, 2000). Recently it was 
observed that high blood levels of homocysteine (Table 3) are present in patients with PD 
receiving L-dopa.  
 
Agent Structure 
Homocysteine 
NH2
SH
OH
O
Rotenone 
O
O O
OCH3
H3CO
O
H
H
Table 3. Neurotoxic agents in Parkinsons’s disease 
On the other hand it is known that the increase in homocysteine is a risk factor for 
atherosclerosis, stroke, vascular disease, and dementia. There are many proposed 
mechanisms for toxicity of homocysteine in promoting neurodegenerative diseases such as 
of Parkinson's and Alzheimer’s diseases (Postuma & Lang, 2004; Seshadri et al., 2002): free 
radicals formation, induction of inflammation, and altered vulnerability of complex I 
mitochondrial respiratory chain. The formation of homocysteine occurs from methionine 
which is converted to S-adenosylmethionine and then demethylated to S-
adenosylhomocysteine, which forms homocysteine. Homocysteine itself is reused to form 
methionine by the action of two enzymes rate-limiting methylenetetrahydrofolate reductase 
(MTHFR) and betaine homocysteine methyltransferase (BHMT). Homocysteine can be 
metabolized to cysteine due to the cystathionine-betasintethase (CBS). The MTHFR requires 
cofactors such as vitamin B12 and folate, while the CBS requires vitamin B6. The 
administration of L-dopa urges COMT activities causing methylation of L-dopa to 3-O-
methyl-dopa and, at the same time, the demethylation of S-adenosylmethionine to S-
adenosylhomocysteine, which rapidly forms homocysteine. Therefore, since the 
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demethylation of S-adenosylmethionine results in an increase of homocysteine, it is easy to 
understand why Parkinson's patients treated with L-dopa have higher levels of 
homocysteine. Consequently, any substance that can reduce blood levels of homocysteine 
should be administered to Parkinson's patients who require L-dopa: COMT inhibitors, 
vitamin B6, folate and vitamin B12. The toxicity of these compounds can be prevented with 
the administration of antioxidants. Complex I of respiratory chain is genetically coded for 
the ring-shaped mitochondrial DNA (mtDNA). A line of evidence, implicating 
mitochondria and mitochondrial genome (mtDNA) in PD pathogenesis, comes from “cybrid 
cells”. While many proteins and enzymes of all electron transport chain complexes are 
coded from nuclear genes, 13 of them are coded in the small circular double-stranded 
mtDNA, located within the mitochondrial matrix. The human mitochondrial genome 
contains 37 genes (16,560 base pairs), including 13 that encode subunits of proteins of 
respiratory chain, and in particular 7 subunits of complex I. Mitochondrial genes exhibit a 
much higher mutation rate compared to nuclear genes and mtDNA is exposed to ROS 
generated during respiration. It is believed, therefore, that the oxidative damage to 
mitochondrial DNA and its mutation can play a role for mitochondrial dysfunction in PD. 
To determine if complex I is genetically abnormal, Swerdlow and colleagues (Swerdlow et 
al., 1996) devised an experiment with cybrid cells, generated to uncouple potential effects of 
a damaged mtDNA from effects of the nuclear DNA. These Swerdlow cybrid cells are 
hybrid cells which combine the nuclear genome from neuroblastoma cells with the 
mitochondrial genome from platelets of PD patients or healthy control subjects. Using these 
cybrid cells, Swerdlow and colleagues confirmed that PD mitochondria were less efficient in 
complex I activity (- 20%) associated with increased free radical production and apoptotic 
cell death (Gu et al., 1998; Swerdlow et al., 1996). Since only mtDNA is derived from the 
donor platelets, the Swerdlow experiment can be interpreted as a suggestion for mtDNA 
transmission of the mitochondrial defect. Besides, many authors suggest that alterations in 
processes of ubiquitination and degradation of proteins by the 26S proteasome can play a 
primary role in the PD pathogenesis (McNaught & Ienner, 2001; McNaught et al., 2001). 
Products of oxidative damage can contribute to substantia nigra degeneration in PD. The 
oxidized proteins can not be adequately ubiquitinated and recognized by the proteasomes 
and accumulated within the cells. The accumulation of ubiquitinated proteins and the loss 
of proteasomal activity can induce mitochondrial dependent apoptotic death of 
dopaminergic neurons in a manner similar to that occurring in the substantia nigra in PD. 
Although rare, some genetic cases of Parkinson’s disease are linked to mutations in a 
synaptic protein called -synuclein that was originally identified from smaller peptides 
isolated in amyloid-containing fractions of Alzheimer disease brains (Hong, 2005). The -
synuclein protein is another aggregating, fibril-forming protein that is a major component of 
the Lewy body lesions characteristic of PD as well as certain cases of Alzheimer (AD) and 
several other neurodegenerative conditions. -Synuclein aggregates show evidence of 
nitration-based oxidative damage that might play a critical role in aggregate formation 
(Giasson et al., 2000). Recent studies have shown that the polyphenol curcumin (the active 
principle of turmeric Curcuma longa) can reduce the aggregation of -synuclein, and its 
administration to cultured cells with -synuclein aggregate formation results in fewer 
aggregates (Ono & Yamada, 2006; Pandey & Galvin, 2005). Also the pesticide rotenone leads 
to the presence of Lewy bodies with aggregation of -synuclein (Sherer et al., 2003). The 
evidence that rotenone, a inhibitor of mitochondrial respiratory chain complex I, causes 
www.intechopen.com
 
Mechanisms in Parkinson’s Disease – Models and Treatments 
 
378 
aggregation of Lewy bodies may means that mitochondrial dysfunction has a role in the 
development of these pathologic fibril-forming proteins in Parkinson’s disease (Dawson & 
Dawson, 2003a). Rajeswary has shown that curcumin protects mouse brain from MPTP-
induced neurotoxicity by virtue of its scavenger activity (Rajeswary, 2006). Moreover, 
curcumin has been shown to protect PC12 cells from MPP+ by inducing bcl-2, a 
antiapoptotic protein, preventing the dissipation of membrane potential of mitochondria 
and reducing then ROS and iNOS levels (Chen et al., 2006). The importance of mitochondria 
in the neuroprotective effect of curcumin has been also emphasized by Mythri et al. (2007), 
who demonstrated that curcumin inhibits the formation of peroxynitrite responsible for the 
damage of respiratory chain complex I. Studies with humans and rodents have 
demonstrated that after oral administration curcumin is transformed to curcumin 
glucuronide and curcumin sulphate, not only in the liver (Rahaman et al., 2006) but also in 
the intestinal tract (Ireson et al., 2002). In these organs, curcumin is also reduced into 
dihydrocurcumin (DHC), tetrahydrocurcumin (THC), hexahydrocurcumin, 
octahydrocurcumin and hexahydrocurcuminol (Ireson et al., 2002; Rahaman et al., 2006); 
curcumin, DHC and THC can be further converted in glucuronide conjugates. It is 
important to note that curcumin and THC have anti-inflammatory activity; in humans and 
rodents curcumin inhibits the activity of cytochrome P450 enzymes, glutathione-transferase 
and UDP-glucuronosyl transferases (Basu et al., 2004; Hayeshi et al., 2007; Thapliyal & 
Maru, 2001). Moreover, it has been shown that a large number of polyphenolic antioxidants 
have a protective effect against the degeneration induced by high levels of ROS and RNS in 
cases of mitochondrial dysfunction. It has been proven that green tea polyphenols have a 
protective effect against 6-hydroxydopamine toxicity in SH-SY5Y cells (Guo et al., 2005). 6-
Hydroxydopamine is a hydroxylated analogue of dopamine, extensively used in rodents. 6-
Hydroxydopamine possess a high affinity for many membrane transporters of 
catecholamines and norepinephrine, allowing the drugs to freely enter both dopaminergic 
and noradrenergic neurons (Bovè et al., 2005). The efficacy of the green tea component 
epigallocatechin 3-gallate has been demonstrated in the MPTP mouse model of Parkinson’s 
disease. It has been shown that in these treated rats there is both loss of dopaminergic 
neurons and attenuation of striatal dopamine levels (Choi et al., 2002). Choi et al. (2002) 
suggest that this protection is mediated by inhibition of NOS expression. Epidemiological 
evidence shows that two caps a day of green tea have a protective effect against the 
Parkinson’s disease development (Chan et al., 1998). Another polyphenol used in the fight 
against Parkinson's disease is the oxyresveratrol, found in large amounts in mulberry wood, 
which has shown potent scavenger activity against ROS and RNS in glial cells exposed to 
hydrogen peroxide (Lorenz et al., 2003). In addition, in a study on 6-hydroxydopamine-
treated neuroblastoma SH-SY5Y cells has been found that the oxyresveratrol drastically 
reduces the production of ROS and reduces also the apoptotic activity of caspase-3 caused 
by damaged mitochondria (Chao et al., 2008). Other important antioxidant is uric acid 
(Ames et al., 1981). Recent studies and epidemiological researches have shown a correlation 
between high levels of uric acid in serum and a lower incidence of Parkinson's disease 
(Annanmaki et al., 2007, Weisskopf et al., 2007; Winquist et al., 2010). It was also seen that 
the uric acid protects against the damage caused by free radicals on the mtDNA (Anderson 
& Harris, 2003), helping to maintain the integrity of the mitochondrial genome and prevent 
possible mutations. In addition, uric acid prevents the death of dopaminergic cells treated 
with rotenone and homocysteine; treatments that increase the production of ROS and act on 
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mitochondrial membrane depolarization (Duan et al., 2002). Most likely uric acid neutralizes 
ROS through the Fenton reaction, thus providing dopaminergic neuroprotection. But we 
have to balance the benefits of dietary supplementation of uric acid on parkinsonism and 
the possible risk of developing gout and cardiovascular problems.  
5. Acetyl-L-carnitine and other nutrients in age-dependent neurodegenerative 
diseases 
A broad spectrum of both genetic and environmental factors has been suggested as 
contributing to the initiation and progression of PD. Among these, an important risk factor 
for the disease is the aging (Parris, 2000). It contributes to PD progression, perhaps because 
of accumulative oxidative damage and decrease of antioxidant capacity. Many evidences 
support the validity of the oxidative stress hypothesis, which suggests that lowered 
functional capacity in aged organisms is the result of an increased generation of reactive 
species. The increased levels of ROS and RNS can cause damage to intracellular 
macromolecules, as DNA, proteins and lipids and consequently impairing the function of 
vulnerable tissues and leading to the accumulation of altered gene products (Calabrese et al., 
2006a). In addition, protein, lipid or glucose oxidation disrupts redox homeostasis and leads 
to accumulation of unfolded or misfolded proteins in the aging brain. For this reason 
Parkinson’s and Alzheimer’s diseases, having a common denominator, production of 
abnormal proteins, mitochondrial dysfunction and oxidative stress, are called “protein 
conformational diseases” (Calabrese et al., 2008). In particular, an unfolded protein response 
conformational disease is condition that arise from dysfunctional aggregation of proteins in 
non-native conformations. This is often associated with multiple metabolic derangements 
that result in the excessive production of ROS and oxidative stress (Zhang et al., 2006). 
Genetic studies have also revealed that aging can be controlled by changes in intracellular 
NAD/NADH ratio regulating sirtuins, a group of proteins linked to aging, metabolism and 
stress tolerance in several organisms. Consistently, the neuroprotective roles of dietary 
antioxidants including for example, curcumin, carnosine, resveratrol and acetyl-L-carnitine 
have been demonstrated through the activation of these redox-sensitive intracellular 
pathways. In particular, acetyl-L-carnitine has been proposed to have beneficial effects in 
preventing the loss of brain function which typically occurs during aging and 
neurodegenerative disorders. In fact, acetyl-L-carnitine treatment has been shown to 
prevent age-related changes in mitochondrial respiration and decrease oxidative stress 
biomarkers thorough the up-regulation of HO-1 (heme oxygenase-1), Hsp70 (heat shock 
protein 70) and superoxide dismutase-2 in senescent rats (Calabrese et al, 2006c). It acts 
through the activaction of transcription factor Nrf2, which after binding to the ARE 
(antioxidant responsive element) in the HO-1 gene, up-regulates both HO-1 and thioredoxin 
reductase (TrxR), thus counteracting pro-oxidant conditions. Heme oxygenase-1 is, in fact, a 
key enzyme in the prevention of brain damage (Calabrese et al., 2006; Maines, 1997; 
Mancuso, 2004). The neuroprotective effects of over-expressed HO-1 has been attributed to 
several factors such as: a) increased level of both cGMP and bcl-2 in neurons; b) inactivation 
of the pro-apoptotic transcription factor p53; c) increase in antioxidant sources, i.e. the iron 
sequestering protein, as ferritin (Panahian, 1999). Hsp70 is, instead, a member of the stress 
protein. Hsc70 (heat shock cognate, the constitutive form), Hsp70 (the inducible form, also 
referred to as Hsp72) and GRP-75 (a constitutively expressed glucose-regulated protein) are 
included in this family (Calabrese et al., 2006b; Yenari et al., 1999). Recently it has been 
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demonstrated that overproduction of Hsp70 leads to protection in several models of 
nervous system injury (Fig. 3). Oxidative stress, which has been suggested to be involved in 
the pathogenesis of PD, may originate in glial cells (Jenner, 2003). This is supported by post-
mortem studies demonstrating the capacity of oxidative stress and oxidizing toxin to induce 
nigral cell degeneration (Olanow et al., 1998). There is evidence to support that there are 
high levels of basal oxidative stress in the substantia nigra pars compacta in the normal 
brain and that this is increased in PD. The brain is therefore particularly sensitive to 
oxidative stress. This is due to several factors: a) the neurons are particularly enriched in 
polyunsaturated fatty acids, prime targets for oxidative attack (Kidd & Levine, 1985); b) the 
brain consumes a high share of the body’s oxygen intake and consequently results in the 
oxyradical formation; c) the activity of the antioxidant enzymes catalase and peroxidase is 
low in the brain, instead the superoxide dismutase is active. They acquire superoxide 
oxyradical and convert it in hydrogen peroxide (H2O2).  
 
 
Fig. 3. The role of acetyl-L-carnitine in cell stress tolerance 
In the absence of catalase and peroxidase, which normally would detoxify these peroxide 
products, that are done by glutathione peroxidase enzyme. This enzyme uses glutathione 
(GSH) as its essential cofactor, and when it is stimulated the brain’s GSH reserves are more 
sensitive to depletion from oxidative attack (Kidd, 1997; Levine & Kidd 1985). As mentioned, 
the substantia nigra is particularly susceptible to oxidative stress and this is due to varied 
and many biochemical process that occur in it. It has a high content of dopamine and its 
metabolism and its “auto-oxidation” could be responsible for the high basal levels of 
oxidative stress. DA has a strong tendency to “auto-oxidation”, generating reactive auto-
metabolites, as 6-hydroxydopamine quinone and dopamine aminochrome, the formation of 
which can be accelerated by free (ionized) iron or by other redox-reactive elements such as 
copper, zinc or manganese (Pezzella, 1997; Youdim, 1989). Then, the degradation of 
dopamine by monoamine oxidase to produce H2O2 could increase the formation of oxidized 
glutathione (GS-SG), suggesting the presence of oxidative stress and impairment of the 
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antioxidant system (Spina & Cohen, 1988). The H2O2 generated is also converted (by Fenton 
reaction), in the presence of the high levels of iron, in toxic hydroxyl radical which can 
damage DNA and other biomolecules (Youdim et al., 1989). It should be noted that an 
extremely high content of iron is concentrated in the substantia nigra zona compacta, and 
various iron-mediated reactions in substantia nigra would potentiate oxidative stress. For 
example ionized iron, or copper and zinc catalyze transformation of the protein -synuclein 
into aggregated form, prominent component of the Lewy aggregates that develop in the SN 
of Parkinson’s patients (Braak & Braak 2000; Paik et al., 2000). Moreover, important role of 
the iron is for dopamine-melanin, macromolecular material formed from the autoxidation of 
dopamine and normally scavenger of free radicals. When it is infiltrated with high levels of 
ionized iron it can drive Fenton reaction converting endogenous hydrogen peroxide to 
hydroxyl radical. The population of melanin-enriched, dopaminergic neurons found in the 
SN’s zona compacta is the worst affected in PD. In the substantia nigra there are high levels 
of melanin and it could act as support matrix upon which ionized iron would catalyze 
oxyradical generation from available hydrogen peroxide or from neuromelanin itself 
(Youdim, et al., 1990).  
6. Conclusion 
Although the selective loss of DA neurons and the accumulation of -synuclein are crucial 
in the development of PD, many evidences indicate that oxidative stress, and mitochondrial 
and proteasome dysfunctions have central role in this pathogenesis. Environmental factors, 
such as exposure to toxins, are also important in late-onset of the disease, whereas in early-
onset PD, genetic factors assume predominant importance. Recently, the identification of 
several genes causing early-onset PD (such as -synuclein; UCHLl, a ubiquitin carboxy-
terminal hydrolase L1; parkin; DJ1, a parkin-associated protein involved with oxidative 
stress; PINK1, a putative serine threonine kinase) has yielded crucial insights into the 
possible pathogenic mechanisms (Dawson & Dawson, 2003b). The use of several 
neurotoxins to produce the clinical symptoms of PD both in vitro and in vivo has allowed to 
understand the molecular mechanism of disease. The functions of mitochondria make these 
subcellular organelles susceptible to oxidative damage, resulting in cell death by apoptosis 
and mtDNA mutations. In this context, the mitochondria represent, therefore, a highly 
promising target for the development of disease biomarkers by use of genetic and 
biochemical approaches.  
The mitochondrial antioxidant/nutrient acetyl-L-carnitine, with its antioxidant energizing 
protective activities and with its trophic effects, at optimal doses, can be an effective and 
safe prevention strategy for PD, offering the possibility of new and innovative therapeutic 
strategies for this neurodegenerative disease. Acetyl-L-carnitine is a highly bioavailable 
molecule, it is thought to penetrate the brain barrier better than carnitine, and it is readily 
converted to carnitine as needed. Experimental evidences suggest that acetyl-L-carnitine 
boosts mitochondrial ATP production and helps to protect mitochondria against oxidative 
attack. This molecule is therefore of great interest for its wide clinical application in various 
neurological disorders, it has beneficial effects in preventing the loss of brain function which 
typically occurs during aging, and its neuroprotective benefits have been observed in the 
hippocampus, prefrontal cortex, substantia nigra and muscarinic receptor portions of the 
brain. These include antioxidant activity, improved mitochondrial energetics, stabilization 
of intracellular membranes and cholinergic neurotransmission. In particular, the most  
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Fig. 4. Biosynthesis and physiological role of acetyl-L-carnitine 
common function of acetyl-L-carnitine is the transport of fatty acids across the inner 
mitochondrial membrane, thereby being involved in the production of energy within the 
brain and in the maintenance of neuron and repairing of damages. Moreover, it has a variety 
of other neuronal effects. It increases protein kinase C (PKC) activity and reverse the age-
related decline in the number of N-methyl-D-aspartate (NMDA) receptors on neuronal 
membranes. In addition, it is thought that it influences the cholinergic system acting as a 
cholinergic receptor agonist; it can also promote the synthesis and the release of 
acetylcholine and stimulates proteins and membrane phospholipids synthesis (Calabrese et 
al., 2005). Acetyl-L-carnitine can also increase the levels of neurotrophins such as nerve 
growth factor (NGF) and can reduce the energetic deficits in brain and phospholipids 
metabolism, probably because it aids mitochondrial functions (Mark et al., 2003). In fact, it 
increases mitochondrial biogenesis and decreases ROS production through the up-
regulation of the PGC-1, as a possible underlying mechanism. In animal models, it partially 
protects the substantia nigra against 1-methyl-4-phenyl-pyridinium (MPP+, active 
metabolite of MPTP) attack, by strengthening the dopaminergic transmission (Bodis-
Wollner et al. 1991; Hongyu et. al., 2010; Sinicropi et al. 2010). In fact, brain histology reveals 
that acetyl-L-carnitine protects neurons in the substantia nigra, which otherwise have been 
devastated by MPTP attack. It has been well observed that long-term acetyl-L-carnitine 
administration in rats increases longevity and improves spatial learning, avoidance learning 
in aged rats, and long-term memory performance (Barnes et al., 1990; Ghiraldi et al., 1989; 
Lysine Methionine
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Markowska et al., 1990). In summary, the protection provided by acetyl-L-carnitine offers 
the possibility of new therapeutic strategies for neurodegenerative diseases (including PD) 
which can share the same final neurotoxic pathway in mitochondria (Fig. 4). 
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Current PD medications treat symptoms; none halt or retard dopaminergic neuron degeneration. The main
obstacle to developing neuroprotective therapies is a limited understanding of the key molecular mechanisms
that provoke neurodegeneration. The discovery of PD genes has led to the hypothesis that misfolding of
proteins and dysfunction of the ubiquitin-proteasome pathway are pivotal to PD pathogenesis. Previously
implicated culprits in PD neurodegeneration, mitochondrial dysfunction, and oxidative stress may also act in
part by causing the accumulation of misfolded proteins, in addition to producing other deleterious events in
dopaminergic neurons. Neurotoxin-based models have been important in elucidating the molecular cascade of
cell death in dopaminergic neurons. PD models based on the manipulation of PD genes should prove valuable
in elucidating important aspects of the disease, such as selective vulnerability of substantia nigra dopaminergic
neurons to the degenerative process.
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